Emerging gene therapies for retinal degenerations.
نویسنده
چکیده
Introduction Our most cherished sense, vision, begins with the process of phototransduction, a process performed by the highly specialized photoreceptor cells of the retina: the rods and cones (Rodieck, 1998). Rod photoreceptor cells are needed for night vision, as they are able to respond to very few photons, while cones are active under bright light conditions and are responsible for color vision. Many people are born with impaired vision, and many others experience loss of vision later in life. For example, age-related macular degeneration (AMD) occurs in 5% of people 80 years old in the U.S. (Rudnicka et al., 2012), while mutations in 200 genes can lead to loss of vision in younger individuals (RetNet; www.sph.uth.tmc.edu/Retnet). This review is focused on emerging strategies that employ gene therapy to combat vision loss, primarily due to mutations that affect photoreceptor cells. Exciting early results from the use of Adeno-associated virus (AAV) vectors in humans to combat Leber’s congenital amaurosis (LCA) (Bainbridge et al., 2008; Maguire et al., 2008), a relatively rare form of congenital blindness, has inspired several groups to employ AAV in a number of ways to combat other genetic diseases. Here, the efforts aimed toward one particular disease, retinitis pigmentosa (RP) (Hartong et al., 2006), will be covered, as there are excellent animal models (Rivas and Vecino, 2009; Fletcher et al., 2011) and it offers some straightforward possibilities to save photoreceptor function and/or photoreceptor cells themselves. Ironically, one of the possibilities is to use optogenetics, rather than gene replacement or knock-down, for restoration of vision (Busskamp and Roska, 2011). It is hoped that we can apply the lessons learned from RP to other diseases that also result in loss of photoreceptor cells, including AMD. Individuals with RP are typically born night-blind, due to rod dysfunction, but initially have full-field, high-acuity color vision. This is in keeping with the expression of many RP disease genes only in rods (www.sph.uth.tmc.edu/Retnet). For reasons that are still unclear (see Overview of therapeutic approaches to RP, below), loss of color vision then follows, and can occur as early as 5 years of age, or much later, in the fifth or sixth decade of life (Hartong et al., 2006; Berson, 2008). The progression of cone dysfunction and death eventually leads to total loss of vision, with the final loss in the center, due to loss of macular vision. The macula comprises only cones in its very center, and is the area of our highest acuity color vision. Invasion of retinal pigmented epithelial cells into the retina leads to the occurrence of black clumps within the retina, and hence the name of the disease. Attenuated retinal blood vessels and optic disc pallor are other hallmarks of the disease (Milam et al., 1998; Berson, 2008). There is no cure for RP, but there are several lines of therapeutic approaches that hold promise, including gene therapy.
منابع مشابه
Cell based therapies in retinal diseases
Background Degenerative retinal diseases, including age related macular degeneration, glaucoma, and hereditary retinal dystrophies are major causes of blindness. The principal defect in these diseases is cell loss which is amenable to both cell based neuroprotective and neuroregenerative therapies. To briefly review the lines of research and potential candidates for cell based therapies among ...
متن کاملA Review of Secondary Photoreceptor Degenerations in Systemic Disease.
Photoreceptor neuronal degenerations are common and incurable causes of human blindness with one in 2000 affected. Approximately, half of all patients are associated with known mutations in more than 200 disease genes. Most retinal degenerations are restricted to the retina (primary retinal degeneration) but photoreceptor degeneration can also be found in a wide variety of systemic and syndromi...
متن کاملRetinal gene therapy 1998: summary of a workshop.
The 1998 Workshop on Retinal Gene Therapy evaluated the potential of gene therapy in treatment of retinal disease. Academic, industry, and private foundation representatives attended. Topics included: determing which retinal diseases are likely candidates for gene therapy, specific retinal degenerations and nonspecific neuronal survival mechanisms, design and use of viral and retroviral vectors...
متن کاملGene and cell-based therapies for inherited retinal disorders: An update.
Retinal degenerations present a unique challenge as disease progression is irreversible and the retina has little regenerative potential. No current treatments for inherited retinal disease have the ability to reverse blindness, and current dietary supplement recommendations only delay disease progression with varied results. However, the retina is anatomically accessible and capable of being m...
متن کاملAAV-mediated gene therapy for retinal disorders in large animal models.
Retinal gene therapy holds great promise for the treatment of inherited and noninherited blinding diseases such as retinitis pigmentosa and age-related macular degeneration. The most widely used vectors for ocular gene delivery are based on adeno-associated virus (AAV) because they elicit minimal immune responses and mediated long-term transgene expression in a variety of retinal cell types. Ex...
متن کاملPhotoreceptor-Based Biomarkers in AOSLO Retinal Imaging
Improved understanding of the mechanisms underlying inherited retinal degenerations has created the possibility of developing much needed treatments for these relentless, blinding diseases. However, standard clinical indicators of retinal health (such as visual acuity and visual field sensitivity) are insensitive measures of photoreceptor survival. In many retinal degenerations, significant pho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of neuroscience : the official journal of the Society for Neuroscience
دوره 32 19 شماره
صفحات -
تاریخ انتشار 2012